Literature DB >> 30567748

Impact of External Quality Assurance on the Quality of Xpert MTB/RIF Testing in Viet Nam.

Vidyanidhi Gumma1, Kyle DeGruy2, Davara Bennett3, Thanh Nguyen Thi Kim4, Heidi Albert5, Kyle B Bond2, Steve Gutreuter2, Heather Alexander2, Lan Ngyuen Thi Phong6, Thomas H Rush6, Nhung Nguyen Viet7, Hung Nguyen Van4.   

Abstract

Following the endorsement of the Xpert MTB/RIF assay (Cepheid, Sunnyvale, CA, USA) by the World Health Organization (WHO) in 2010, Viet Nam's National Tuberculosis Control Program (NTP) began using GeneXpert instruments in NTP laboratories. In 2013, Viet Nam's NTP implemented an Xpert MTB/RIF external quality assurance (EQA) program in collaboration with the U.S. Centers for Disease Control and Prevention (CDC) and the Foundation for Innovative New Diagnostics (FIND). Proficiency-testing (PT) panels comprising five dried tube specimens (DTS) were sent to participating sites approximately twice a year from October 2013 to July 2016. The number of enrolled laboratories increased from 22 to 39 during the study period. Testing accuracy was assessed by comparing reported and expected results; percentage scores were assigned; and feedback reports were provided to sites. On-site evaluation (OSE) was conducted for underperforming laboratories. The results from the first five rounds demonstrate the positive impact of PT and targeted OSE visits on testing quality. On average, for every additional round of feedback, the odds of achieving PT scores of ≥80% increased 2.04-fold (95% confidence interval, 1.39- to 3.00-fold). Future work will include scaling up PT to all sites and maintaining the performance of participating laboratories while developing local panel production capacity.

Entities:  

Keywords:  Mycobacterium tuberculosis; molecular diagnostics; proficiency testing; quality assurance

Mesh:

Substances:

Year:  2019        PMID: 30567748      PMCID: PMC6425173          DOI: 10.1128/JCM.01669-18

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  13 in total

1.  Analytic results of HIV-1 testing using blind proficiency testing.

Authors:  K M Peddecord; A S Benenson; L K Hofherr; D P Francis; R S Garfein; K L Ferran; R N Taylor; W O Schalla; M S Ascher
Journal:  Clin Lab Sci       Date:  1992 May-Jun

2.  Countrywide roll-out of Xpert(®) MTB/RIF in Swaziland: the first three years of implementation.

Authors:  W Sikhondze; T Dlamini; D Khumalo; G Maphalala; S Dlamini; T Zikalala; H Albert; J Wambugu; K Tayler-Smith; E Ali; S Ade; A D Harries
Journal:  Public Health Action       Date:  2015-06-21

3.  Are peripheral microscopy centres ready for next generation molecular tuberculosis diagnostics?

Authors:  Claudia M Denkinger; Ioana Nicolau; Andrew Ramsay; Pamela Chedore; Madhukar Pai
Journal:  Eur Respir J       Date:  2013-08       Impact factor: 16.671

4.  Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial.

Authors:  Grant Theron; Lynn Zijenah; Duncan Chanda; Petra Clowes; Andrea Rachow; Maia Lesosky; Wilbert Bara; Stanley Mungofa; Madhukar Pai; Michael Hoelscher; David Dowdy; Alex Pym; Peter Mwaba; Peter Mason; Jonny Peter; Keertan Dheda
Journal:  Lancet       Date:  2013-10-28       Impact factor: 79.321

5.  Impact of proficiency testing program for laboratories conducting early diagnosis of HIV-1 infection in infants in low- to middle-income countries.

Authors:  Albert Garcia; Shambavi Subbarao; Guoqing Zhang; Linda Parsons; John Nkengasong; Chin-Yih Ou; Dennis Ellenberger
Journal:  J Clin Microbiol       Date:  2013-12-18       Impact factor: 5.948

6.  The patient impact of point-of-care vs. laboratory placement of Xpert(®) MTB/RIF.

Authors:  C F Hanrahan; K Clouse; J Bassett; L Mutunga; K Selibas; W Stevens; L Scott; I Sanne; A Van Rie
Journal:  Int J Tuberc Lung Dis       Date:  2015-07       Impact factor: 2.373

7.  Scaling up HIV rapid testing in developing countries: comprehensive approach for implementing quality assurance.

Authors:  Bharat S Parekh; Mireille B Kalou; George Alemnji; Chin-Yih Ou; Guy-Michel Gershy-Damet; John N Nkengasong
Journal:  Am J Clin Pathol       Date:  2010-10       Impact factor: 2.493

Review 8.  Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test.

Authors:  Stephen D Lawn; Peter Mwaba; Matthew Bates; Amy Piatek; Heather Alexander; Ben J Marais; Luis E Cuevas; Timothy D McHugh; Lynn Zijenah; Nathan Kapata; Ibrahim Abubakar; Ruth McNerney; Michael Hoelscher; Ziad A Memish; Giovanni Battista Migliori; Peter Kim; Markus Maeurer; Marco Schito; Alimuddin Zumla
Journal:  Lancet Infect Dis       Date:  2013-03-24       Impact factor: 25.071

9.  Multicenter feasibility study to assess external quality assessment panels for Xpert MTB/RIF assay in South Africa.

Authors:  Lesley Scott; Heidi Albert; Chris Gilpin; Heather Alexander; Kyle DeGruy; Wendy Stevens
Journal:  J Clin Microbiol       Date:  2014-04-30       Impact factor: 5.948

Review 10.  Development, roll-out and impact of Xpert MTB/RIF for tuberculosis: what lessons have we learnt and how can we do better?

Authors:  Heidi Albert; Ruvandhi R Nathavitharana; Chris Isaacs; Madhukar Pai; Claudia M Denkinger; Catharina C Boehme
Journal:  Eur Respir J       Date:  2016-07-13       Impact factor: 16.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.